Alex Puissant is currently group leader of a young ATIP / AVENIR team created in January 2017 at the Institute of Hematology (IUH) at the Saint-Louis Hospital, in Paris (France).

After receiving his Ph.D. degree (2010) at the Mediterranean Center of Molecular Medecine (C3M) in Nice (France), Alex did his post-doctoral training at the Dana Farber Cancer Institute (DFCI/Harvard) in Boston (MA, USA), prior to joining Inserm in 2016.

His research is mainly focused on understanding mechanisms of progression and chemoresistance of a highly aggressive and deadly form of leukemia termed as Acute Myeloid Leukemias (AML). To do so, he has developed syngenic model of AML to set up screens using doxycycline-inducible shRNA libraries. He also performed long-term culture methods of primary leukemic blasts from patients with AML in order to identify cellular regulators of leukemic stem cell function.

Main Collaborations:

• Kim Stegmaier − DFCI (Boston, USA)
• Kris C. Wood − Duke University (Durham, USA)
• Ben Ebert − Brigham & Women's Hospital (Boston, USA)
• Dirk Heckl − Hannover Medical School (Hannover, Germany)
• Florian Grebien − University of Veterinary Medicine (Vienna, Austria)
• Hind Medyouf − Institute for Tumor Biology (Frankfurt, Germany)
• Camille Lobry – Institut de Recherche Saint-Louis (Paris, France)
• Didier Bouscary / Jérôme Tamburini − Cochin Institute (Paris, France)
• Patrick Auberger − C3M (Nice, France)